Skip to main content

Day: March 9, 2026

Safe Harbor Financial CEO Highlights Growth Platform Launch, Debt Elimination, and Financial Stabilization in Letter to Shareholders

DENVER, March 09, 2026 (GLOBE NEWSWIRE) — SHF Holdings, Inc., d/b/a Safe Harbor Financial (“Safe Harbor” or the “Company”) (NASDAQ: SHFS), a leading fintech platform serving the banking, lending, and financial services needs of the regulated cannabis and hemp industries, today released a letter to shareholders from Terrance Mendez, Chief Executive Officer of Safe Harbor. Dear Fellow Shareholders, Today, Safe Harbor has a strong financial base and is ready to grow: we are debt-free, hold more than $6 million in cash, and have secured a long-term agreement with a major customer that is expected to generate at least $10.5 million in incremental cash flow. Here is a summary of the past year and why we believe the next chapter is significantly more valuable than the last. The Numbers Tell the Story The single most important thing I...

Continue reading

FuelCell Energy Delivers Strong Q1’26 Revenue Growth vs Q1’25; Advances Data Center Power Strategy

DANBURY, Conn., March 09, 2026 (GLOBE NEWSWIRE) — FuelCell Energy, Inc. (NASDAQ: FCEL) today reported financial results for its first quarter ended January 31, 2026. First Quarter Fiscal 2026 Highlights (All comparisons are year-over-year unless otherwise noted)Revenue of $30.5 million, compared to $19.0 million, an increase of approximately 61% Gross loss of $(5.9) million, compared to $(5.2) million, an increase of approximately 13% Loss from operations of $(26.3) million, compared with $(32.9) million, a decrease of approximately 20% Net loss per share attributable to common stockholders was $(0.49), compared with $(1.42) Backlog of $1.17 billion, compared to $1.31 billion, a decrease of approximately 10.8%“During the first fiscal quarter, we delivered strong revenue growth, sharpened operating discipline, and strengthened...

Continue reading

Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update

Presented data at ESMO 2025 demonstrating promising efficacy with CRB-701 in head and neck squamous cell carcinoma (HNSCC) and cervical cancer CRB-701 data for both indications is expected in mid-2026 with focus on durability and patient stratification Reported 14-day CRB-913 SAD/MAD data demonstrating potent and rapid weight loss of 2.9% with favorable GI safety On schedule to complete 12-week CRB-913 obesity study (n=240) in summer 2026  Completed $75 million public offering in Q4 2025 extending cash runway into 2028  NORWOOD, Mass., March 09, 2026 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage company focused on promising new therapies in oncology and obesity, today provided a corporate update and reported financial results for the fourth quarter and year...

Continue reading

Nayax Reports Fourth Quarter and Full Year 2025 Results 

Full year revenue of $400.4 million, recurring revenue growth of 29%Full year organic revenue growth of 24% (1)Net income of $35.5 million with Adjusted EBITDA of $61.1 million (1)2026 Revenue guidance of $510 million – $520 million2026 Adjusted EBITDA(1) guidance of $85 million – $90 million  HERZLIYA, Israel, March 09, 2026 (GLOBE NEWSWIRE) — Nayax Ltd. (Nasdaq: NYAX, TASE: NYAX), a global commerce payments and loyalty platform designed to help merchants scale their business, today announced its financial results for the fourth quarter and year ended December 31, 2025. “Nayax delivered strong 2025 results and a very solid fourth quarter. We generated net income of $35.5 million compared to a loss just one year ago, a milestone that reflects the true earnings power of our business model. The company continued to scale...

Continue reading

Tevogen Names Leadership Team to Execute Diversified Growth Strategy

WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) — Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the appointment of interim leaders across its core business verticals to execute the first phase of its diversified growth strategy. In this first phase, Tevogen is evaluating strategic opportunities that, if completed, are expected to operate as subsidiaries of the Company and could collectively generate annual revenues exceeding $50 million. The Company expects these transactions to close by the second quarter of 2026, subject to customary due diligence and definitive agreements. Leadership Designations:Digital Health: Arpita Patel and Wojtek Stobinski Generics: Sadiq Khan and David Banko Contract Research: William Keane Biotech: Lori Grosso Artificial Intelligence: Mittul MehtaAbout Tevogen Tevogen...

Continue reading

No. 6/2026 – CeMat A/S acquires right of perpetual usufruct to land plot in Bielany, Warsaw

Nasdaq Copenhagen                                                                                    Nikolaj Plads 6DK-1067 Copenhagen K    Copenhagen, 9 March 2026ANNOUNCEMENT no. 6/2026CeMat A/S acquires right of perpetual usufruct to land plot in Bielany, Warsaw CeMat A/S is pleased to announce that it has obtained a binding decision confirming its acquisition by law of the right of perpetual usufruct (RPU) to 75% of the shares in a plot of land designated for road use on Wólczyńska Street, in the Bielany district of Warsaw. The decision relates to a land plot covering a total area of 800 sqm, and grants the company the right of perpetual usufruct until 2089. This binding decision provides the legal basis for registering the RPU in the land and mortgage register. The acquired plot completes the entire internal road network within...

Continue reading

Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit

MELBOURNE, Australia and SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced  that David Stamler, M.D., Chief Executive Officer of Alterity, will participate in the Bell Potter Healthcare Horizons Summit taking place 12-13 March 2026 in Sorrento, Australia. At the conference, Dr. Stamler will participate in a fireside chat entitled, “Optimising Late-stage Clinical Trials to Increase the Odds,” and will also host 1-on-1 investor meetings. About Alterity Therapeutics Limited  Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The...

Continue reading

Alexander’s to Sell Rego Park I for Net Proceeds of $202 Million

PARAMUS, N.J., March 09, 2026 (GLOBE NEWSWIRE) — Alexander’s, Inc. (NYSE: ALX) announced today that it has entered into an agreement to sell its Rego Park I property to Northwell Health, Inc. The gross purchase price is $235.5 million and the net proceeds will be $202 million. The property is unencumbered. The property is located at the intersection of Queens Boulevard and Junction Boulevard, adjacent to the Long Island Expressway, in Queens, New York. The Rego Park I property is comprised of a vacant, three-story, 338,000 gross leasable square foot structure built in 1959 and a 1,236 space parking garage, located on 5.9 acres. Alexander’s recently vacated the property by relocating tenants to its adjacent Rego Park II shopping center. The financial statement gain will be approximately $147 million and the tax gain will be approximately...

Continue reading

Siris Agrees to Acquire a Majority Stake in TAKKION from Apollo Funds

Siris to partner with TAKKION to provide full life-cycle renewable energy solutions to meet the increasing demand for power WEST PALM BEACH, Fla. and CENTENNIAL, Colo., March 09, 2026 (GLOBE NEWSWIRE) — Siris (together with its affiliates, “Siris”), a leading private equity firm targeting services companies that support critical technology infrastructure, today announced a definitive agreement to acquire a majority stake in TAKKION, a premier integrated services provider to the renewable energy industry that generated approximately $600 million in revenue in 2025, from funds managed by Apollo (NYSE:APO) (the “Apollo Funds”). The transaction is expected to close in Q2 2026, subject to customary closing conditions. Founded in 2019, TAKKION is a scaled, diversified energy services platform operating in an increasingly attractive industry...

Continue reading

Aecon Utilities expands U.S. electrical utility services capabilities with acquisition of Duna Services and an interest in KNX Utility Services

TORONTO, March 09, 2026 (GLOBE NEWSWIRE) — Aecon Group Inc. (TSX: ARE) (“Aecon” or the “Company”) announced today that its subsidiary, Aecon Utilities Group Inc. (“Aecon Utilities”), has acquired Duna Services, LLC (“Duna Services”) and its subsidiaries Arc American, LLC and C.A. Advanced, LLC, and a 49% interest in KNX Utility Services, LLC (“KNX”) from Ryker Holdings Inc. for a base purchase price of US$60 million with the potential for additional contingent proceeds (the “Transaction”). The Transaction is being financed through Aecon Utilities’ standalone committed revolving credit facility. Headquartered in Wakarusa, Indiana, Duna Services and its subsidiaries have approximately 350 employees and bring 14 years of experience providing underground and overhead electrical distribution, transmission, substation maintenance, and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.